WO2004026877A1 - Imidazopyrazines as cyclin dependent kinase inhibitors - Google Patents
Imidazopyrazines as cyclin dependent kinase inhibitors Download PDFInfo
- Publication number
- WO2004026877A1 WO2004026877A1 PCT/US2003/029209 US0329209W WO2004026877A1 WO 2004026877 A1 WO2004026877 A1 WO 2004026877A1 US 0329209 W US0329209 W US 0329209W WO 2004026877 A1 WO2004026877 A1 WO 2004026877A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- aryl
- group
- alkyl
- heteroaryl
- Prior art date
Links
- 0 *c(nc1Br)c[n]2c1ncc2 Chemical compound *c(nc1Br)c[n]2c1ncc2 0.000 description 2
- LSROBYZLBGODRN-UHFFFAOYSA-N NN(CCC1)C1=O Chemical compound NN(CCC1)C1=O LSROBYZLBGODRN-UHFFFAOYSA-N 0.000 description 2
- GTGSLQCDVIMUST-UHFFFAOYSA-N O=C1NC(c2ccccc2)=C[n]2c1ncc2 Chemical compound O=C1NC(c2ccccc2)=C[n]2c1ncc2 GTGSLQCDVIMUST-UHFFFAOYSA-N 0.000 description 2
- JTMVFJNBPAFFDK-UHFFFAOYSA-N Bc(nc1[BrH]C)cnc1N Chemical compound Bc(nc1[BrH]C)cnc1N JTMVFJNBPAFFDK-UHFFFAOYSA-N 0.000 description 1
- WRUHYHILALSVJY-UHFFFAOYSA-N Brc1cnc(c(NCc2cnccc2)n2)[n]1cc2Br Chemical compound Brc1cnc(c(NCc2cnccc2)n2)[n]1cc2Br WRUHYHILALSVJY-UHFFFAOYSA-N 0.000 description 1
- XIYNRDCFTYPQPM-UHFFFAOYSA-N Cc1nc(Br)c[n]2c1ncc2Br Chemical compound Cc1nc(Br)c[n]2c1ncc2Br XIYNRDCFTYPQPM-UHFFFAOYSA-N 0.000 description 1
- VNHGRYDXWHFJKR-UHFFFAOYSA-N Clc1nc(-c2ccccc2)c[n]2c1ncc2 Chemical compound Clc1nc(-c2ccccc2)c[n]2c1ncc2 VNHGRYDXWHFJKR-UHFFFAOYSA-N 0.000 description 1
- ALXNFMZJNVTFFZ-UHFFFAOYSA-N O=C1N(CCCNc2nc(-c(cccc3)c3Cl)c[n]3c2ncc3Br)CCC1 Chemical compound O=C1N(CCCNc2nc(-c(cccc3)c3Cl)c[n]3c2ncc3Br)CCC1 ALXNFMZJNVTFFZ-UHFFFAOYSA-N 0.000 description 1
- MQOWEASININIFV-UHFFFAOYSA-N O=C1NC(c(cccc2)c2Cl)=C[n]2c1ncc2 Chemical compound O=C1NC(c(cccc2)c2Cl)=C[n]2c1ncc2 MQOWEASININIFV-UHFFFAOYSA-N 0.000 description 1
- VZSLLTQIFCCBOT-UHFFFAOYSA-N OC(CCCC1)C1Nc(nc1NCc2cnccc2)c[n]2c1ncc2Br Chemical compound OC(CCCC1)C1Nc(nc1NCc2cnccc2)c[n]2c1ncc2Br VZSLLTQIFCCBOT-UHFFFAOYSA-N 0.000 description 1
- XLASHLHZSLENRA-UHFFFAOYSA-N OCC(CCCC1)C1Nc(nc1NCc2cnccc2)c[n]2c1ncc2Br Chemical compound OCC(CCCC1)C1Nc(nc1NCc2cnccc2)c[n]2c1ncc2Br XLASHLHZSLENRA-UHFFFAOYSA-N 0.000 description 1
- PEHOKAZOKJDWHU-UHFFFAOYSA-N OCCC(CCCC1)N1c(nc1NCc2cnccc2)c[n]2c1ncc2Br Chemical compound OCCC(CCCC1)N1c(nc1NCc2cnccc2)c[n]2c1ncc2Br PEHOKAZOKJDWHU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to imidazo[1 ,2-a]pyrazine compounds useful as protein kinase inhibitors (such as for example, the inhibitors of the cyclin- dependent kinases, mitogen-activated protein kinase (MAPK/ERK), glycogen synthase kinase 3(GSK3beta) and the like), pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases such as, for example, cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases.
- diseases such as, for example, cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases.
- Protein kinase inhibitors include kinases such as, for example, the inhibitors of the cyclin-dependent kinases (CDKs), mitogen activated protein kinase (MAPK/ERK), glycogen synthase kinase 3 (GSK3beta), and the like.
- CDKs cyclin-dependent kinases
- MAPK/ERK mitogen activated protein kinase
- GSK3beta glycogen synthase kinase 3
- the cyclin- dependent kinases are serine/threonine protein kinases, which are the driving force behind the cell cycle and cell proliferation.
- Individual CDK's such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8 and the like, perform distinct roles in cell cycle progression and can be classified as either G1 , S, or G2M phase enzymes.
- CDK2 and CDK4 are of particular interest because their activities are frequently misregulated in a wide variety of human cancers.
- CDK2 activity is required for progression through G1 to the S phase of the cell cycle, and CDK2 is one of the key components of the G1 checkpoint.
- Checkpoints serve to maintain the proper sequence of cell cycle events and allow the cell to respond to insults or to proliferative signals, while the loss of proper checkpoint control in cancer cells contributes to tumorgenesis.
- the CDK2 pathway influences tumorgenesis at the level of tumor suppressor function (e.g. p52, RB, and p27) and oncogene activation (cyclin E).
- CDK inhibitors are known.
- flavopiridol (Formula I) is a nonselective CDK inhibitor that is currently undergoing human clinical trials, A. M. Sanderowicz et al, J. Clin. Oncol. (1998) 16, 2986-2999.
- CDK inhibitors include, for example, olomoucine (J. Vesely er a/, Eur. J. Biochem., (1994) 224. 771-786) and roscovitine (I. Meijer et al, Eur. J. Biochem., (1997) 243, 527-536).
- U.S. 6,107,305 describes certain pyrazolo[3,4-b] pyridine compounds as CDK inhibitors.
- An illustrative compound from the '305 patent has the Formula II:
- the present invention provides a novel class of imidazo[1 ,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
- the present application discloses a compound, or pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula III:
- R is selected from the group consisting of H, halogen, aryl, heteroaryl, cycloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, -C(O)R 7 ,
- each of said aryl, heteroaryl, cycloalkyl, arylalkyl, alkenyl, heterocyclyl and the heterocyclyl moieties whose structures are shown immediately above for R can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF 3 , CN, -OCF 3 , -OR 6 , -C(O)R 7 , -NR 5 R 6 , -C(O 2 )R 6 , -C(O)NR 5 R 6 , -(CHR 5 ) n OR 6 , -SR 6 , -S(O 2 )R 7 , -S(O 2 )NR 5 R 6 , -N(R 5 )S(O 2 )R 7 , -N(R 5 )C(O)R 7 and -N
- R 1 is H, halogen, or alkyl
- R 2 is selected from the group consisting of R 9 , alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, -CF 3 , -C(O)R 7 , alkyl substituted with 1-6 R 9 groups which groups can be the same or different with each R 9 being
- each of said aryl, heteroaryl, cycloalkyl, arylalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF 3 , CN, -OCF 3 , -OR 6 , -C(O)R 7 , -NR 5 R 6 , -C(O 2 )R 6 , -C(O)NR 5 R 6 , -SR 6 , -S(O 2 )R 7 , -S(O 2 )NR 5 R 6 , -N(R 5 )S(O 2 )R 7 , -N(R 5 )C(O)R 7 and -N(R 5 )C(O)NR 5 R 6 ;
- R 3 is selected from the group consisting of H, aryl, heteroaryl, heterocyclyl, -(CHR 5 ) n -aryl, - (CHR 5 ) n -heteroaryl, -(CHR 5 ) n -cycloalkyl,
- each of said aryl, heteroaryl and heterocyclyl can be substituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , CN, -OCF 3 , -OR 5 , -NR 5 R 6 , -C(O 2 )R 5 , -C(O)NR 5 R 6 , -SR 6 , -S(O 2 )R 6 , -S(O 2 )NR 5 R 6 , -N(R 5 )S(O 2 )R 7 , -N(R 5 )C(O)R 7 and -N(R 5 )C(O)NR 5 R 6 ;
- R 5 is H or alkyl;
- R 6 is selected from the group consisting of H, alkyl, aryl, heteroaryl
- R 8 is selected from the group consisting of R 6 , -C(O)NR 5 R 6 , -S(O 2 )NR 5 R 6 , -C(O)R 7 , -C(O 2 )R 6 , -S(O 2 )R 7 and -(CH 2 )-aryl;
- R 9 is selected from the group consisting of halogen, CN, NR 5 R 6 ,
- the compounds of Formula III can be useful as protein kinase inhibitors and can be useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
- the present invention discloses imidazo[1,2-a]pyrazine compounds which are represented by structural Formula III, or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as described above.
- R is selected from the group consisting of H, halogen, aryl, heteroaryl, alkenyl and -C(O)R 7 , wherein each of said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, CF 3 , CN, - OCF 3 , and -OR 6 .
- R 1 is H or lower alkyl.
- R 2 is selected from the group consisting of halogen, alkyl, aryl, heteroaryl, alkenyl and -C(O)R 7 , wherein each of said alkyl, aryl and heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, CF 3 , CN, - OCF 3 , and -OR 6 .
- R 3 is selected from the group consisting of H, aryl, heteroaryl, -(CHR 5 ) n -aryl, - (CHR 5 ) n -heteroaryl, -(CHR 5 ) n -OR 6 , -C(O)R 6 , cycloalkyl,
- each of said aryl and heteroaryl can be substituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, CF 3 , CN, -C(O 2 )R 5 and - S(O 2 )R 6 .
- R 5 is H or lower alkyl.
- n is 1 to 3.
- R is selected from the group consisting of H, phenyl and heteroaryl.
- R 1 is H, Br or methyl.
- R 2 is F, Cl, Br, I, aryl, alkenyl, heteroaryl or CF 3 .
- R 3 is phenyl, (pyrid-2-yl)methyl, (pyrid-3- yl)methyl, (pyrid-4-yl)methyl, 2-[(pyrid-3-yl)]ethyl, 2-[(pyrid-4-yl)]ethyl, 2-ylpropanol, 3-ylpropyl-10pyrrolidin-2-one, or-C(O)CH 3 , wherein said pyridyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of F, Cl, Br, CF 3 , lower alkyl, methoxy and CN.
- R 5 is H.
- m is 0.
- n 1 or 2.
- ventive group of compounds is shown in Table 1.
- Another embodiment discloses compounds of the formula: ormula:
- Patient includes both human and animals.
- “Mammal” means humans and other mammalian animals.
- Alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain.
- More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain.
- Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain.
- Lower alkyl means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
- substituted alkyl means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, aikylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , carboxy and -C(O)O-alkyl.
- suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
- Alkynyl means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
- Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain.
- Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain.
- “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
- Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl.
- substituted alkynyl means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
- Aryl means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
- Non- limiting examples of suitable aryl groups include phenyl and naphthyl.
- Heteroaryl means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.
- Preferred heteroaryls contain about 5 to about 6 ring atoms.
- the "heteroaryl” can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom.
- a nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
- Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyi, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1 ,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyrid
- Aralkyl or “arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non- limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
- Alkylaryl means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non- limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
- Cycloalkyl means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms.
- the cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
- suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like, as well as partially saturated species such as, for example, indanyl, tetrahydronaphthyl and the like.
- Ring system substituent means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkyl
- Ring system substituent may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system.
- Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH 3 ) 2 - and the like which form moieties such as, for example:
- Heterocyclyl means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
- Preferred heterocyclyls contain about 5 to about 6 ring atoms.
- the prefix aza, oxa orthia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
- Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), - N(CBz), -N(Tos) group and the like; such protections are also considered part of this invention.
- the heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
- the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like. It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring: there is no -OH attached directly to carbons marked 2 and 5.
- Alkynylalkyl means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
- Heteroaralkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl. "Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
- acyl means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described.
- the bond to the parent moiety is through the carbonyl.
- Preferred acyls contain a lower alkyl.
- suitable acyl groups include formyl, acetyl and propanoyl.
- Aroyl means an aryl-C(O)- group in which the aryl group is as previously described.
- the bond to the parent moiety is through the carbonyl.
- suitable groups include benzoyl and 1- naphthoyl.
- Alkoxy means an alkyl-O- group in which the alkyl group is as previously described.
- suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
- the bond to the parent moiety is through the ether oxygen.
- Aryloxy means an aryl-O- group in which the aryl group is as previously described.
- suitable aryloxy groups include phenoxy and naphthoxy.
- the bond to the parent moiety is through the ether oxygen.
- Alkyloxy means an aralkyl-O- group in which the aralkyl group is as previously described.
- suitable aralkyloxy groups include benzyloxy and 1 - or 2-naphthalenemethoxy.
- the bond to the parent moiety is through the ether oxygen.
- Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
- suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
- Arylthio means an aryl-S- group in which the aryl group is as previously described.
- suitable arylthio groups include phenylthio and naphthylthio.
- the bond to the parent moiety is through the sulfur.
- Alkylthio means an aralkyl-S- group in which the aralkyl group is as previously described.
- Non-limiting example of a suitable aralkylthio group is benzylthio.
- the bond to the parent moiety is through the sulfur.
- Alkoxycarbonyl means an alkyl-O-CO- group.
- suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl.
- the bond to the parent moiety is through the carbonyl.
- Aryloxycarbonyl means an aryl-O-C(O)- group.
- suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
- the bond to the parent moiety is through the carbonyl.
- Aralkoxycarbonyl means an aralkyl-O-C(O)- group.
- Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.
- Alkylsulfonyl means an alkyl-S(O 2 )- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
- Arylsulfonyl means an aryl-S(O 2 )- group. The bond to the parent moiety is through the sulfonyl.
- substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- optionally substituted means optional substitution with the specified groups, radicals or moieties.
- isolated or “in isolated form” for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof.
- purified or “in purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
- protecting groups When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991 ), Wiley, New York.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- Prodrugs and solvates of the compounds of the invention are also contemplated herein.
- the term "prodrug”, as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of Formula III or a salt and/or solvate thereof.
- a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.
- Solvate means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate” is a solvate wherein the solvent molecule is H 2 O. "Effective amount” or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the CDK(s) and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
- the compounds of Formula III can form salts which are also within the scope of this invention.
- Reference to a compound of Formula III herein is understood to include reference to salts thereof, unless otherwise indicated.
- the term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
- zwitterions inner salts may be formed and are included within the term "salt(s)" as used herein.
- Salts of the compounds of the Formula III may be formed, for example, by reacting a compound of Formula III respectively with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonat.es (also known as tosylates,) and the like.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
- All stereoisomers for example, geometric isomers, optical isomers and the like
- of the present compounds including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs
- those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- the use of the terms "salt”, “solvate” "prodrug” and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
- the compounds according to the invention have pharmacological properties; in particular, the compounds of Formula III can be inhibitors of protein kinases such as, for example, the inhibitors of the cyclin-dependent kinases, mitogen-activated protein kinase (MAPK/ERK), glycogen synthase kinase 3(GSK3beta) and the like.
- the cyclin dependent kinases (CDKs) include, for example, CDC2 (CDK1 ), CDK2, CDK4, CDK5, CDK6, CDK7 and CDK8.
- novel compounds of Formula III are expected to be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
- proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
- proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
- the compounds of Formula III can be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosar
- inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
- any disease process e.g., benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
- Compounds of Formula III may also be useful in the treatment of Alzheimer's disease, as suggested by the recent finding that CDK5 is involved in the phosphorylation of tau protein (J. Biochem, (1995) 117, 741-749). Compounds of Formula III may induce or inhibit apoptosis. The apoptotic response is aberrant in a variety of human diseases.
- Compounds of Formula III as modulators of apoptosis, will be useful in the treatment of cancer (including but not limited to those types mentioned hereinabove), viral infections (including but not limited to herpevirus, poxvirus, Epstein- Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia,
- Compounds of Formula III can modulate the level of cellular RNA and DNA synthesis. These agents would therefore be useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus).
- viral infections including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus.
- Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
- Compounds of Formula III may also be useful in inhibiting tumor angiogenesis and metastasis.
- Compounds of Formula III may also act as inhibitors of other protein kinases, e.g., protein kinase C, her2, raf 1, MEK1 , MAP kinase, EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, weel kinase, Src, Abl and thus be effective in the treatment of diseases associated with other protein kinases.
- Another aspect of this invention is a method of treating a mammal (e.g., human) having a disease or condition associated with the CDKs by administering a therapeutically effective amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound to the mammal.
- a preferred dosage is about 0.001 to 500 mg/kg of body weight/day of the compound of Formula III.
- An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of a compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound.
- the compounds of this invention may also be useful in combination (administered together or sequentially) with one or more of anti-cancer treatments such as radiation therapy, and/or one or more anti-cancer agents selected from the group consisting of cytostatic agents, cytotoxic agents (such as for example, but not limited to, DNA interactive agents (such as cisplatin or doxorubicin)); taxanes (e.g.
- topoisomerase II inhibitors such as etoposide
- topoisomerase I inhibitors such as irinotecan (or CPT-11), camptostar, or topotecan
- tubulin interacting agents such as paclitaxel, docetaxel or the epothilones
- hormonal agents such as tamoxifen
- thymidilate synthase inhibitors such as 5-fluorouracil
- anti-metabolites such as methoxtrexate
- alkylating agents such as temozolomide (TEMODARTM from Schering-Plough Corporation, Kenilworth, New Jersey), cyclophosphamide
- Farnesyl protein transferase inhibitors such as, SARASARTM(4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]pyr
- interferons such as, for example, intron (from Schering-Plough Corporation), Peg-lntron (from Schering-Plough Corporation); hormonal therapy combinations; aromatase combinations; ara-C, adriamycin, cytoxan, and gemcitabine.
- anti-cancer agents include but are not limited to Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin (ELOXATINTM from Sanofi-Synthelabo Pharmaeuticals, France), Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide
- such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agent or treatment within its dosage range.
- the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897.
- Compounds of Formula III may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate.
- the invention is not limited in the sequence of administration; compounds of Formula III may be administered either prior to or after administration of the known anticancer or cytotoxic agent.
- cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. Cancer Research, (1997) 57, 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.
- this invention includes combinations comprising an amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate thereof, and an amount of one or more anti-cancer treatments and anti-cancer agents listed above wherein the amounts of the compounds/ treatments result in desired therapeutic effect.
- the pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays.
- the exemplified pharmacological assays which are described later have been carried out with the compounds according to the invention and their salts.
- compositions which comprise at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
- inert, pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
- the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
- Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18 th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
- Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration. Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
- a pharmaceutically acceptable carrier such as an inert compressed gas, e.g. nitrogen.
- solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
- liquid forms include solutions, suspensions and emulsions.
- the compounds of the invention may also be deliverable transdermally.
- the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
- the compounds of this invention may also be delivered subcutaneously.
- the compound is administered orally.
- the pharmaceutical preparation is in a unit dosage form.
- the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
- the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 100 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.
- the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
- a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
- Another aspect of this invention is a kit comprising a therapeutically effective amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.
- kits comprising an amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound and an amount of at least one anticancer therapy and/or anti-cancer agent listed above, wherein the amounts of the two or more ingredients result in desired therapeutic effect.
- the invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.
- API-100 mass spectrometer and Shimadzu SCL-10A LC column Altech platinum C18, 3 micron, 33mm x 7mm ID; gradient flow: 0 min - 10% CH 3 CN, 5 min - 95%
- N-Bromosuccinimide (“NBS”) (180 mg, 1.0 mmol) in anhydrous CH 3 CN (5 mL) was added under N 2 to a stirred solution of the product from Preparative Example 5 (230 mg, 1.0 mmol) in anhydrous CH 3 CN (5 mL) and CH 2 CI 2 (3 mL). The mixture was stirred at 25°C for 5 hr and the solvent was then evaporated. Chromatography on silica gel with CH 2 CI 2 /EtOac (10:1 ) afforded white solid (294 mg, 96 %).
- N-iodosuccinimide 450 mg, 2.0 mmol
- anhydrous CH 3 CN 10 mL
- 1,2- dichloroethane 10 mL
- the mixture was refluxed for 30 hr and the solvent was then evaporated.
- EXAMPLE 50 A stock solution of the title compound from Preparative Example 8 (1.2g) in anhydrous CH 3 CN (120mL) was prepared and an aliquot (1mL, 10mg, 0.0291 mmoles) was placed in each of the wells of an X-Block containing PS- DMAP resin (77.6mg, 0.1164mmoles). Freshly prepared 1 M solutions of a library of 96 primary amines (0.0873mL, 0.0873mmoles) were added to each of the 96 wells of the X-Block. The unit was sealed and heated at 60-70°C for 26h.
- the block was cooled, opened and filtered into a new X-Block containing PS- Isocyanate resin (35mg, 0.073mmoles) and PS-Trisamine resin (35mg, 0.15mmoles) and the PS-DMAP resin was washed with CH 3 CN (0.5mL/well).
- the X-Block was sealed and shaken at 25°C for 71 h.
- the block was opened, filtered and each well was washed with CH 3 CN (0.5mL).
- the wells were evaporated to dryness on a Speedvac concentrator.
- the samples were analyzed by LCMS and samples that were ⁇ 90% pure were further purified as needed by preparative LCMS.
- BACULOVIRUS CONSTRUCTIONS Cyclins A and E were cloned into pFASTBAC (Invitrogen) by PCR, with the addition of a GluTAG sequence (EYMPME) at the amino-terminal end to allow purification on anti-GluTAG affinity columns.
- the expressed proteins were approximately 46kDa (cyclin E) and 50kDa (cyclin A) in size.
- CDK2 was also cloned into pFASTBAC by PCR, with the addition of a haemaglutinin epitope tag at the carboxy-terminal end (YDVPDYAS). The expressed protein was approximately 34kDa in size.
- ENZYME PRODUCTION Recombinant baculoviruses expressing cyclins A, E and CDK2 were infected into SF9 cells at a multiplicity of infection (MOI) of 5, for 48 hrs. Cells were harvested by centrifugation at 1000 RPM for 10 minutes. Cyclin-containing (E or A) pellets were combined with CDK2 containing cell pellets and lysed on ice for 30 minutes in five times the pellet volume of lysis buffer containing 50mM Tris pH 8.0, 0.5% NP40, 1mM DTT and protease/phosphatase inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Mixtures were stirred for 30-60 minutes to promote cyclin-CDK2 complex formation.
- MOI multiplicity of infection
- CDK2 kinase assays (either cyclin A or E-dependent) were performed in low protein binding 96-weII plates (Corning Inc, Corning, New York). Enzyme was diluted to a final concentration of 50 ug/ml in kinase buffer containing 50mM Tris pH 8.0, 10mM MgC ⁇ l mM DTT, and 0.1 mM sodium orthovanadate. The substrate used in these reactions was a biotinylated peptide derived from Histone H1 (from Amersham, UK). The substrate was thawed on ice and diluted to 2 uM in kinase buffer.
- the reaction was stopped by adding 200 ⁇ l of stop buffer containing 0.1% Triton X-100, 1mM ATP, 5mM EDTA, and 5 mg/ml streptavidine coated SPA beads (from Amersham, UK) for 15 minutes.
- the SPA beads were then captured onto a 96-weII GF/B filter plate (Packard/Perkin Elmer Life Sciences) using a Filtermate universal harvester (Packard/Perkin Elmer Life Sciences.). Non-specific signals were eliminated by washing the beads twice with 2M NaCl then twice with 2 M
- ICgn DETERMINATION Dose-response curves were plotted from inhibition data generated, each in duplicate, from 8 point serial dilutions of inhibitory compounds. Concentration of compound was plotted against % kinase activity, calculated by CPM of treated samples divided by CPM of untreated samples. To generate IC 50 values, the dose-response curves were then fitted to a standard sigmoidal curve and IC 50 values were derived by nonlinear regression analysis.
- IC 50 values for the compounds of the invention are shown in Table 7. These kinase activities were generated by using cyclin A or cyclin E using the above-described assay.
- the compounds of the present invention exhibit excellent CDK inhibitory properties.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2499756A CA2499756C (en) | 2002-09-23 | 2003-09-19 | Imidazopyrazines as cyclin dependent kinase inhibitors |
NZ538685A NZ538685A (en) | 2002-09-23 | 2003-09-19 | Imidazopyrazines as cyclin dependent kinase inhibitors |
MXPA05003120A MXPA05003120A (en) | 2002-09-23 | 2003-09-19 | Imidazopyrazines as cyclin dependent kinase inhibitors. |
JP2004537904A JP4799864B2 (en) | 2002-09-23 | 2003-09-19 | Imidazopyrazine as a cyclin-dependent kinase inhibitor |
DE60317353T DE60317353T2 (en) | 2002-09-23 | 2003-09-19 | IMIDAZOPYRAZINES AS CDK INHIBITORS |
EP03754658A EP1543008B1 (en) | 2002-09-23 | 2003-09-19 | Imidazopyrazines as cyclin dependent kinase inhibitors |
AU2003272476A AU2003272476B2 (en) | 2002-09-23 | 2003-09-19 | Imidazopyrazines as cyclin dependent kinase inhibitors |
HK05105312A HK1072056A1 (en) | 2002-09-23 | 2005-06-27 | Imidazopyrazines as cyclin dependent kinase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41299702P | 2002-09-23 | 2002-09-23 | |
US60/412,997 | 2002-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004026877A1 true WO2004026877A1 (en) | 2004-04-01 |
Family
ID=32030951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/029209 WO2004026877A1 (en) | 2002-09-23 | 2003-09-19 | Imidazopyrazines as cyclin dependent kinase inhibitors |
Country Status (19)
Country | Link |
---|---|
US (2) | US6919341B2 (en) |
EP (1) | EP1543008B1 (en) |
JP (1) | JP4799864B2 (en) |
KR (1) | KR20050057520A (en) |
CN (1) | CN1694886A (en) |
AR (1) | AR041347A1 (en) |
AT (1) | ATE377600T1 (en) |
AU (1) | AU2003272476B2 (en) |
CA (1) | CA2499756C (en) |
DE (1) | DE60317353T2 (en) |
ES (1) | ES2293015T3 (en) |
HK (1) | HK1072056A1 (en) |
MX (1) | MXPA05003120A (en) |
MY (1) | MY134589A (en) |
NZ (2) | NZ538685A (en) |
PE (1) | PE20050081A1 (en) |
TW (1) | TW200413378A (en) |
WO (1) | WO2004026877A1 (en) |
ZA (1) | ZA200502375B (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005429A1 (en) * | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005019220A2 (en) * | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
US6919340B2 (en) | 2002-04-19 | 2005-07-19 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
WO2007032936A3 (en) * | 2005-09-09 | 2007-05-03 | Schering Corp | Azafused cyclin dependent kinase inhibitors |
WO2007058873A2 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as cyclin depentend kinase inhibitors |
US7312341B2 (en) | 2002-09-09 | 2007-12-25 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2008156614A2 (en) * | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
DE102007032349A1 (en) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo, pyrazolopyrazines and imidazotriazines and their use |
WO2009017701A2 (en) * | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
WO2009024585A2 (en) | 2007-08-21 | 2009-02-26 | Biofocus Dpi Limited | Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis |
JP2009515888A (en) * | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | Imidazopyrazine as a protein kinase inhibitor |
JP2009515882A (en) * | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | Methods for inhibiting protein kinases |
WO2009074259A1 (en) * | 2007-12-13 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Triazolotriazines and triazolopyrazines and the use thereof |
US7557104B2 (en) * | 2006-06-06 | 2009-07-07 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2009138176A1 (en) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines as gsk3beta-inhibitors |
US7759374B2 (en) | 2002-08-23 | 2010-07-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2010088368A2 (en) | 2009-01-29 | 2010-08-05 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US7875638B2 (en) | 2002-08-23 | 2011-01-25 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
WO2011092120A1 (en) * | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
WO2011113862A1 (en) | 2010-03-18 | 2011-09-22 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines |
WO2011151259A1 (en) | 2010-06-01 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines |
WO2012080230A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080234A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080236A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080228A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012085038A1 (en) * | 2010-12-22 | 2012-06-28 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
US8440667B2 (en) | 2008-12-08 | 2013-05-14 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8455493B2 (en) | 2008-12-08 | 2013-06-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8697699B2 (en) | 2008-02-13 | 2014-04-15 | Gilead Connecticut, Inc. | Imidazopyrazine SYK inhibitors |
US8716282B2 (en) | 2009-10-30 | 2014-05-06 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
US8859543B2 (en) | 2010-03-09 | 2014-10-14 | Janssen Pharmaceutica Nv | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US9346811B2 (en) | 2011-03-01 | 2016-05-24 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
US9382256B2 (en) | 2013-07-30 | 2016-07-05 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
US9550784B2 (en) | 2012-07-09 | 2017-01-24 | Beerse Pharmaceutica NV | Inhibitors of phosphodiesterase 10 enzyme |
US9562056B2 (en) | 2010-03-11 | 2017-02-07 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
US9580433B2 (en) | 2013-06-12 | 2017-02-28 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
US9687492B2 (en) | 2013-12-04 | 2017-06-27 | Gilead Sciences, Inc. | Methods for treating cancers |
US9707236B2 (en) | 2014-07-14 | 2017-07-18 | Gilead Sciences, Inc. | Combination methods for treating cancers |
US9751886B2 (en) | 2013-06-12 | 2017-09-05 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
US9828350B2 (en) | 2010-06-09 | 2017-11-28 | Janssen Pharmaceutica Nv | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) |
US9834559B2 (en) | 2013-06-12 | 2017-12-05 | Janssen Pharmaceutica Nv | 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE) |
US9845326B2 (en) | 2011-03-09 | 2017-12-19 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors |
US9968601B2 (en) | 2013-12-23 | 2018-05-15 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US10106524B2 (en) | 2014-12-18 | 2018-10-23 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
US11384082B2 (en) | 2017-08-25 | 2022-07-12 | Kronos Bio, Inc. | Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4579351B2 (en) * | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | Synthesis of epothilone and its intermediates and analogs and uses thereof |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
TW200412967A (en) * | 2002-09-23 | 2004-08-01 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
KR20050057520A (en) * | 2002-09-23 | 2005-06-16 | 쉐링 코포레이션 | Imidazopyrazines as cyclin dependent kinase inhibitors |
US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
JP2008510734A (en) | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | Kinase inhibitor |
PL1799230T3 (en) * | 2004-08-27 | 2013-05-31 | Cyclacel Ltd | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP2397478A1 (en) * | 2005-01-14 | 2011-12-21 | CGI Pharmaceuticals, Inc. | 1,3-diaryl substituted ureas as modulators of kinase activity. |
US7709468B2 (en) * | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CA2653506A1 (en) * | 2006-05-31 | 2007-12-06 | Galapagos Nv. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
MX2009005011A (en) * | 2006-11-08 | 2009-05-20 | Schering Corp | Imidazopyrazines as protein kinase inhibitors. |
WO2008063558A2 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
WO2008065198A1 (en) * | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
CN101652069A (en) * | 2007-03-27 | 2010-02-17 | 艾博特公司 | Novel imidazo-based heterocycles |
WO2008138843A1 (en) * | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases |
WO2008138842A1 (en) * | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
DK2419429T3 (en) * | 2009-04-16 | 2014-06-23 | Ct Nac De Investigaciones Oncológicas Cnio | IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN CHINAS |
EP2473041B1 (en) | 2009-09-04 | 2018-03-07 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
JP2017516855A (en) * | 2014-05-28 | 2017-06-22 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | Certain protein kinase inhibitors |
BR112018009879A2 (en) | 2015-11-18 | 2018-11-13 | Genzyme Corp | biomarker of polycystic kidney disease and its uses |
TW202214634A (en) * | 2020-06-09 | 2022-04-16 | 大陸商賽諾哈勃藥業(成都)有限公司 | Heterocyclic compound and derivative thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028605A (en) * | 1986-05-12 | 1991-07-02 | L'universite De Montpellier I | 8-alkylaminoimidazo(1,2-a)pyrazines and derivatives, their preparation and their application in therapy |
WO2002050079A1 (en) * | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5137876A (en) * | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
DK0778277T3 (en) | 1995-12-08 | 2003-10-27 | Pfizer | Substituted heterocyclic derivatives as CRF antagonists |
JPH1166560A (en) * | 1997-08-15 | 1999-03-09 | Sony Corp | Method and apparatus for recording of optical information |
US6589952B2 (en) | 2000-07-14 | 2003-07-08 | Bristol-Myers Squibb Pharma Company | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders |
CN100457753C (en) | 2000-07-26 | 2009-02-04 | 布里斯托尔-迈尔斯斯奎布公司 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
KR20050008691A (en) | 2002-04-19 | 2005-01-21 | 셀룰러 지노믹스 아이엔씨 | Imidazo[1,2-a]Pyrazin-8-ylamines Method Of Making And Method Of Use Thereof |
TW200412967A (en) * | 2002-09-23 | 2004-08-01 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
KR20050057520A (en) * | 2002-09-23 | 2005-06-16 | 쉐링 코포레이션 | Imidazopyrazines as cyclin dependent kinase inhibitors |
-
2003
- 2003-09-19 KR KR1020057004841A patent/KR20050057520A/en not_active Application Discontinuation
- 2003-09-19 AU AU2003272476A patent/AU2003272476B2/en not_active Ceased
- 2003-09-19 CN CNA038251779A patent/CN1694886A/en active Pending
- 2003-09-19 TW TW092125979A patent/TW200413378A/en unknown
- 2003-09-19 MY MYPI20033585A patent/MY134589A/en unknown
- 2003-09-19 AT AT03754658T patent/ATE377600T1/en not_active IP Right Cessation
- 2003-09-19 EP EP03754658A patent/EP1543008B1/en not_active Expired - Lifetime
- 2003-09-19 WO PCT/US2003/029209 patent/WO2004026877A1/en active IP Right Grant
- 2003-09-19 US US10/665,005 patent/US6919341B2/en not_active Expired - Lifetime
- 2003-09-19 ES ES03754658T patent/ES2293015T3/en not_active Expired - Lifetime
- 2003-09-19 PE PE2003000961A patent/PE20050081A1/en not_active Application Discontinuation
- 2003-09-19 NZ NZ538685A patent/NZ538685A/en unknown
- 2003-09-19 JP JP2004537904A patent/JP4799864B2/en not_active Expired - Fee Related
- 2003-09-19 MX MXPA05003120A patent/MXPA05003120A/en active IP Right Grant
- 2003-09-19 CA CA2499756A patent/CA2499756C/en not_active Expired - Fee Related
- 2003-09-19 DE DE60317353T patent/DE60317353T2/en not_active Expired - Lifetime
- 2003-09-19 NZ NZ563374A patent/NZ563374A/en unknown
- 2003-09-22 AR ARP030103441A patent/AR041347A1/en unknown
-
2005
- 2005-01-31 US US11/047,524 patent/US7432265B2/en not_active Expired - Fee Related
- 2005-03-22 ZA ZA200502375A patent/ZA200502375B/en unknown
- 2005-06-27 HK HK05105312A patent/HK1072056A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028605A (en) * | 1986-05-12 | 1991-07-02 | L'universite De Montpellier I | 8-alkylaminoimidazo(1,2-a)pyrazines and derivatives, their preparation and their application in therapy |
WO2002050079A1 (en) * | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
Non-Patent Citations (3)
Title |
---|
K. ZURBONSEN ET AL.: "Antiproliferative effects of Imidazo[1,2-a]pyrazine derivatives on the Dami cell Line", BIOCHEMICAL PHARMACOLOGY, vol. 54, 1997, pages 365 - 371, XP002267821 * |
VITSE O ET AL: "New Imidazo(1,2-a)pyrazine Derivatives with Brochodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 7, 1999, pages 1059 - 1065, XP002257093, ISSN: 0968-0896 * |
ZURBONSEN K ET AL: "APOPTOTIC EFFECTS OF IMIDAZO1,2-ALPHAPYRAZINE DERIVATIVES IN THE HUMAN DAMI CELL LINE", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 320, 1997, pages 215 - 221, XP002924561, ISSN: 0014-2999 * |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6919340B2 (en) | 2002-04-19 | 2005-07-19 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
US7875638B2 (en) | 2002-08-23 | 2011-01-25 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US8110590B2 (en) | 2002-08-23 | 2012-02-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US8513429B2 (en) | 2002-08-23 | 2013-08-20 | Sloan-Kettering Insitute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7759374B2 (en) | 2002-08-23 | 2010-07-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7312341B2 (en) | 2002-09-09 | 2007-12-25 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof |
US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
US7189723B2 (en) | 2003-02-10 | 2007-03-13 | Cgi Pharmaceuticals, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005005429A1 (en) * | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005019220A2 (en) * | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
WO2005019220A3 (en) * | 2003-08-11 | 2005-03-24 | Cellular Genomics Inc | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US7700773B2 (en) | 2005-09-09 | 2010-04-20 | Schering Corporation | 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors |
WO2007032936A3 (en) * | 2005-09-09 | 2007-05-03 | Schering Corp | Azafused cyclin dependent kinase inhibitors |
WO2007058873A3 (en) * | 2005-11-10 | 2007-07-19 | Schering Corp | Imidazopyrazines as cyclin depentend kinase inhibitors |
WO2007058873A2 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as cyclin depentend kinase inhibitors |
JP2009515888A (en) * | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | Imidazopyrazine as a protein kinase inhibitor |
JP2009515882A (en) * | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | Methods for inhibiting protein kinases |
JP2009515883A (en) * | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | A novel imidazopyrazine as a cyclin-dependent kinase inhibitor |
US7557104B2 (en) * | 2006-06-06 | 2009-07-07 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2008156614A3 (en) * | 2007-06-14 | 2009-02-12 | Schering Corp | Imidazopyrazines as protein kinase inhibitors |
WO2008156614A2 (en) * | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
US8476267B2 (en) | 2007-07-11 | 2013-07-02 | Bayer Intellectual Property Gmbh | Imidazo-, pyrazolopyrazines and imidazotriazines and their use |
WO2009007029A1 (en) * | 2007-07-11 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Imidazo-, pyrazolopyrazines and imidazotriazines and their use |
DE102007032349A1 (en) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo, pyrazolopyrazines and imidazotriazines and their use |
JP2010532772A (en) * | 2007-07-11 | 2010-10-14 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Imidazo-, pyrazolopyrazine and imidazotriazines and their use |
WO2009017701A3 (en) * | 2007-07-31 | 2009-05-07 | Schering Corp | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
WO2009017701A2 (en) * | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
WO2009024585A2 (en) | 2007-08-21 | 2009-02-26 | Biofocus Dpi Limited | Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis |
EP2567960A2 (en) | 2007-08-21 | 2013-03-13 | Biofocus DPI Limited | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis |
WO2009074259A1 (en) * | 2007-12-13 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Triazolotriazines and triazolopyrazines and the use thereof |
US8697699B2 (en) | 2008-02-13 | 2014-04-15 | Gilead Connecticut, Inc. | Imidazopyrazine SYK inhibitors |
US8436003B2 (en) | 2008-05-15 | 2013-05-07 | Bayer Intellectual Property Gmbh | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines |
WO2009138176A1 (en) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines as gsk3beta-inhibitors |
DE102008023801A1 (en) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted imidazo and triazolopyrimidines, imidazo and pyrazolopyrazines and imidazotriazines |
US8748607B2 (en) | 2008-12-08 | 2014-06-10 | Gilead Connecticut, Inc. | Imidazopyrizine syk inhibitors |
US10093684B2 (en) | 2008-12-08 | 2018-10-09 | Gilead Connecticut, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US9796718B2 (en) | 2008-12-08 | 2017-10-24 | Gilead Connecticut, Inc. | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine |
US8765761B2 (en) | 2008-12-08 | 2014-07-01 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-{4-[2-methyl-1-(morpholin-4-yl)propan-2-yl]phenyl}imidazo[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a syk inhibitor |
US9212191B2 (en) | 2008-12-08 | 2015-12-15 | Gilead Connecticut, Inc. | 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor |
US9120811B2 (en) | 2008-12-08 | 2015-09-01 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma |
US8440667B2 (en) | 2008-12-08 | 2013-05-14 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8455493B2 (en) | 2008-12-08 | 2013-06-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8962835B2 (en) | 2008-12-08 | 2015-02-24 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
US8796270B2 (en) | 2008-12-08 | 2014-08-05 | Gilead Connecticut, Inc. | N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US9567348B2 (en) | 2008-12-08 | 2017-02-14 | Gilead Connecticut, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors |
WO2010088368A2 (en) | 2009-01-29 | 2010-08-05 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
US8716282B2 (en) | 2009-10-30 | 2014-05-06 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
WO2011092120A1 (en) * | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
US8772279B2 (en) | 2010-01-29 | 2014-07-08 | Nerviano Medical Sciences S.R.L. | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators |
US8859543B2 (en) | 2010-03-09 | 2014-10-14 | Janssen Pharmaceutica Nv | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
US9562056B2 (en) | 2010-03-11 | 2017-02-07 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
US10842803B2 (en) | 2010-03-11 | 2020-11-24 | Kronos Bio, Inc. | Imidazopyridines Syk inhibitors |
US10092583B2 (en) | 2010-03-11 | 2018-10-09 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
WO2011113862A1 (en) | 2010-03-18 | 2011-09-22 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines |
US9468642B2 (en) | 2010-03-18 | 2016-10-18 | Bayer Intellectual Property Gmbh | Imidazopyrazines |
WO2011151259A1 (en) | 2010-06-01 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines |
US9828350B2 (en) | 2010-06-09 | 2017-11-28 | Janssen Pharmaceutica Nv | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) |
WO2012080230A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080236A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2012080228A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
JP2013545778A (en) * | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 6-substituted imidazopyrazines for use as MPS-1 and TKK inhibitors in the treatment of hyperproliferative disorders |
WO2012080234A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
EA022409B1 (en) * | 2010-12-22 | 2015-12-30 | Янссен Фармацевтика Нв | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
WO2012085038A1 (en) * | 2010-12-22 | 2012-06-28 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
JP2014500293A (en) * | 2010-12-22 | 2014-01-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 5,6-Dihydro-imidazo [1,2-a] pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
KR101866987B1 (en) * | 2010-12-22 | 2018-07-19 | 얀센 파마슈티카 엔.브이. | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
KR20130132556A (en) | 2010-12-22 | 2013-12-04 | 얀센 파마슈티카 엔.브이. | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
US9840507B2 (en) | 2010-12-22 | 2017-12-12 | Janssen Pharmaceutica, Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
US9346811B2 (en) | 2011-03-01 | 2016-05-24 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
US9845326B2 (en) | 2011-03-09 | 2017-12-19 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
US9550784B2 (en) | 2012-07-09 | 2017-01-24 | Beerse Pharmaceutica NV | Inhibitors of phosphodiesterase 10 enzyme |
US9580433B2 (en) | 2013-06-12 | 2017-02-28 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
US9834559B2 (en) | 2013-06-12 | 2017-12-05 | Janssen Pharmaceutica Nv | 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE) |
US9751886B2 (en) | 2013-06-12 | 2017-09-05 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
US9382256B2 (en) | 2013-07-30 | 2016-07-05 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
US10266539B2 (en) | 2013-07-30 | 2019-04-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
US9949932B2 (en) | 2013-07-30 | 2018-04-24 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
US9918939B2 (en) | 2013-07-30 | 2018-03-20 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
US9687492B2 (en) | 2013-12-04 | 2017-06-27 | Gilead Sciences, Inc. | Methods for treating cancers |
US9974792B2 (en) | 2013-12-04 | 2018-05-22 | Gilead Sciences, Inc. | Methods for treating cancers |
US9968601B2 (en) | 2013-12-23 | 2018-05-15 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US10342794B2 (en) | 2013-12-23 | 2019-07-09 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US10828299B2 (en) | 2013-12-23 | 2020-11-10 | Kronos Bio, Inc. | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US10080756B2 (en) | 2014-07-14 | 2018-09-25 | Gilead Sciences, Inc. | Combination methods for treating cancers |
US9707236B2 (en) | 2014-07-14 | 2017-07-18 | Gilead Sciences, Inc. | Combination methods for treating cancers |
US10106524B2 (en) | 2014-12-18 | 2018-10-23 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase |
US11384082B2 (en) | 2017-08-25 | 2022-07-12 | Kronos Bio, Inc. | Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors |
US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JP4799864B2 (en) | 2011-10-26 |
TW200413378A (en) | 2004-08-01 |
EP1543008B1 (en) | 2007-11-07 |
NZ538685A (en) | 2008-02-29 |
US6919341B2 (en) | 2005-07-19 |
CN1694886A (en) | 2005-11-09 |
ES2293015T3 (en) | 2008-03-16 |
MY134589A (en) | 2007-12-31 |
MXPA05003120A (en) | 2005-06-22 |
US20050130980A1 (en) | 2005-06-16 |
KR20050057520A (en) | 2005-06-16 |
ATE377600T1 (en) | 2007-11-15 |
EP1543008A1 (en) | 2005-06-22 |
AU2003272476B2 (en) | 2007-07-05 |
JP2006507253A (en) | 2006-03-02 |
US20040063715A1 (en) | 2004-04-01 |
DE60317353D1 (en) | 2007-12-20 |
AU2003272476A1 (en) | 2004-04-08 |
DE60317353T2 (en) | 2008-08-28 |
PE20050081A1 (en) | 2005-03-01 |
US7432265B2 (en) | 2008-10-07 |
HK1072056A1 (en) | 2005-08-12 |
NZ563374A (en) | 2009-06-26 |
CA2499756C (en) | 2011-07-12 |
CA2499756A1 (en) | 2004-04-01 |
AR041347A1 (en) | 2005-05-11 |
ZA200502375B (en) | 2005-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1543008B1 (en) | Imidazopyrazines as cyclin dependent kinase inhibitors | |
AU2003275031B2 (en) | Novel imidazopyrazines as cyclin dependent kinase inhibitors | |
EP1720883B1 (en) | Pyrazolotriazines as kinase inhibitors | |
CA2499639C (en) | Imidazopyridines as cyclin dependent kinase inhibitors | |
EP1534712A2 (en) | Pyrazolo[1,5-a]pyrimidine compounds as cyclin dependent kinase inhibitors | |
WO2004022560A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
IL167432A (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
AU2007200401A1 (en) | Imidazopyrazines as cyclin dependent kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE EG ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NI NO NZ PG PH PL PT RO RU SC SE SG SK SL SY TJ TM TN TR TT TZ UA UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 167318 Country of ref document: IL Ref document number: 538685 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003754658 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500573 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2499756 Country of ref document: CA Ref document number: 1020057004841 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/003120 Country of ref document: MX Ref document number: 2005/02375 Country of ref document: ZA Ref document number: 200502375 Country of ref document: ZA Ref document number: 2004537904 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003272476 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038251779 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057004841 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003754658 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003272476 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003754658 Country of ref document: EP |